| Heart
    Disease Still Killing Millions of Women. [United States] Angioplasty, bypass surgery
    and cholesterol-lowering medications are among the many interventions that have brought a
    sharp decrease in heart disease deaths in recent years. But, as Dr. Sharon Hayes of the
    Mayo Clinic points out, there is one big problem. The death rates in women have not
    declined as much as they have in men, she says. The latest statistics show a
    shocking difference. | 
  
    | Study: Stitches Bar Female
    Bladder Problems. [United States] A few well-placed stitches can prevent bladder
    problems in tens of thousands of women each year who have surgery to fix sagging internal
    organs, a new study suggests. ''It's a very common problem in women, and this is the first
    time we've been able to demonstrate that an operation can actually prevent urinary
    incontinence,'' said Dr. Linda Brubaker of Loyola University, who led the study. Results
    were published in today's New England Journal of Medicine. The nationwide, federally
    funded study was stopped early because the benefits were so clear. It involved 322 women
    having surgery for pelvic organ prolapse, an uncomfortable condition that is basically a
    hernia of the vagina. Frequent childbirth increases the chances of this, and about 200,000
    women a year have surgery for it. But the operation, which consists of implanting mesh to
    hold the vagina in place, often unveils underlying bladder control problems. Doctors
    wanted to see whether adding a second step, called the Burch procedure, could prevent
    this. | 
  
    | Estrogen
    Therapy Boosts Clotting Risk in Postmenopausal Women. [United States] Estrogen therapy
    appears to increase the risk of blood clots in the veins of postmenopausal women who have
    had their uterus removed. These latest results from the Women's Health Initiative (WHI)
    were unexpected, even to the study's lead author. "It surprised us all how few
    benefits have come out of this and how many negatives," said Dr. J. David Curb, a
    professor of geriatric medicine at the University of 
Hawaii and president/director of the
    Pacific Health Research Institute, both in Honolulu. "This is not where I would have
    predicted we would be. I was a believer [that estrogen would not increase the risk of
    blood clots]. The data have convinced me that I was wrong." The risk is still less
    than that of estrogen plus progestin, the combination hormone therapy given if a woman
    still has her uterus. The study appears in the April 10 issue of the Archives of Internal
    Medicine.  | 
  
    | Two Breast Cancer Studies
    Question Old Treatments. [United 
States]
 Two important studies published Wednesday
    challenge conventional thoughts about treating and avoiding breast cancer. One suggests
    doctors may eventually be able to identify women who do not need chemotherapy. The other
    says women who have had hysterectomies can take estrogen to relieve symptoms of menopause
    without increasing their risk of breast cancer. The first study, published in the Journal
    of the American Medical Association, indicates that many of the 70 percent of women whose
    cancers are fed by estrogen get so much benefit from estrogen-blocking hormonal therapy
    that chemotherapy provides few if any additional advantages. The caveat, though, is that
    there is as yet no reliable way to identify the women who may not need chemotherapy from
    those who would be helped by it. Currently, guidelines call for women to get chemotherapy
    if their tumors are of a certain size. The second paper, also published Wednesday in the
    Journal of the American Medical Association, involved a U.S. government study of more than
    10,700 healthy women whose uteruses had been removed. The question was: What are the
    health consequences of taking estrogen for the relief of menopausal symptoms? The new
    report does not apply to most menopausal women, but only to those who have had
    hysterectomies. In this case, the Women's Health Initiative found that estrogen did not
    increase the women's risk of breast cancer. But they did have more abnormal mammograms
    results, usually requiring that the test be repeated, and more breast biopsies. The study
    ended early, at the end of February 2004, when the investigators found that estrogen
    increased the risk of strokes and of blood clots in the legs. The study also found that
    estrogen taken alone increased the risk of dementia in women over age 65, decreased the
    risk of hip fractures and had no effect on heart disease. But the question of estrogen's
    effects on breast cancer risk had been uncertain until now, when the women had been
    followed for seven years. The results in women with hysterectomies contrast with those
    from another arm of the study involving women who had not had hysterectomies and who took
    estrogen and progesterone. In that case the hormone combination led to more breast cancer
    and more heart disease. It remains a puzzle why estrogen, which can fuel the growth of
    many breast cancers, did not increase the breast cancer risk in this study.  | 
  
    | Osteoporosis Drug Shown to
    Decrease Chances of Breast Cancer. [United States] A drug already in widespread use to
    prevent bone thinning in women past menopause can also reduce their risk of invasive
    breast cancer, researchers reported. The drug is raloxifene, sold as Evista. It is the
    second drug found to reduce the risk of breast cancer. The first was tamoxifen, whose
    brand name is Nolvadex, which is approved to treat breast cancer and also prevent it in
    women at high risk for the disease. A study, sponsored by the U.S.-based National Cancer
    Institute and released Monday, has found that raloxifene works as well as tamoxifen in
    women at high risk for breast cancer, and that it may have fewer side effects. In those
    cases, each drug halves the risk of invasive breast cancer. "We feel raloxifene is
    the winner of this trial," said Dr. D. Lawrence Wickerham, associate chairman of the
    National Surgical Adjuvant Breast and Bowel Project, which coordinated the experiment.
    Other experts said it was not clear whether raloxifene had significant advantages over
    tamoxifen. Although raloxifene reduces the risk of invasive breast cancer, it does not
    reduce the risk of an earlier form of the disease that can become invasive if it is not
    caught in time. Tamoxifen cuts that risk in half. Raloxifene has Food and Drug
    Administration approval to treat just osteoporosis in postmenopausal women. Its maker, Eli
    Lilly, is expected to apply for additional permission to market it for breast cancer
    prevention in high- risk postmenopausal women. Because it is already sold, doctors can
    prescribe it as they see fit, the common practice called "off-label" use.
    Raloxifene and tamoxifen can cause significant side effects, including small increases in
    risk of uterine cancer and blood clots and menopausal symptoms. | 
  
    | Drug Found
    to Cut Risk of Breast Cancer. [United States] A drug used to treat osteoporosis
    reduced the risk of breast cancer by half among women predisposed to develop the disease,
    according to data released Monday. The drug, known as raloxifene and sold under the brand
    name Evista, worked as well as tamoxifen, the only drug approved to lower the risk of
    breast cancer. Women taking raloxifene also had fewer serious side effects than those on
    tamoxifen. ''This is really good news for women,'' said Dr. Leslie Ford, a National Cancer
    Institute researcher who was one of the study's leaders. ``It's a drug that's already used
    by 500,000 women for treatment and prevention of osteoporosis, and now we have an
    additional benefit.'' In the seven-year study, researchers followed nearly 20,0000
    post-menopausal women whose age, family history and medical history put them at high risk
    for breast cancer. The women, whose average age was 58, were randomly assigned to take
    tamoxifen or raloxifene. Researchers announced the results Monday. In both groups, roughly
    20 women per thousand developed breast cancer -- about half the rate that would be
    expected without treatment. Both drugs are known to increase the risk of blood clots, and
    the rate of strokes and heart attacks was the same in both groups. | 
  
    | 
Many
    Cancer Survivors Stop Mammographies. [United 
States] More than a third of breast
    cancer survivors gradually stop getting annual mammographies, according to a new study.
    The results may indicate women grow complacent about medical screening once they get past
    the medical scare, said the study's lead author, Dr. Chyke Doubeni 
of the University of Massachusetts.
    Others said it's more likely survivors avoid screenings because they dread a recurrence of
    the cancer and additional treatment. "They're fearful something's going to be
    found," said Dr. Kathryn Edmiston, a Worcester, 
Mass., oncologist who specializes in
    breast cancer patients. The study found just 63 percent of women were getting annual
    mammographies five years after breast cancer surgery. The findings are reported in Cancer,
    a medical journal published by the Atlanta-based American Cancer Society. About 2.3
    million U.S. women have 
been treated for breast cancer, and they are considered to be at
    three times the risk for tumors in the other, unaffected breast than women with no such
    medical history. | 
  
    | Deaths After RU-486.
    [United States] 
Reports that up to six American and one Canadian women have died after
    pill-induced abortions in recent years are making the regimen based on RU-486 look a lot
    less attractive than once thought. Conservatives in Congress and anti-abortion
    organizations are demanding that RU-486 be withdrawn from the market. That seems premature
    given the uncertainties and small number of deaths in a still-unfolding story. But women
    seeking an abortion will need to weigh the risks and benefits carefully before deciding
    which method to choose. Based on admittedly shaky data, pill-induced or medical abortions
    look riskier and less certain to fully terminate a pregnancy than surgical abortions. The
    deaths after medical abortions, though very rare, have some alarming and puzzling
    characteristics. Most of the women were healthy, had apparently successful abortions, died
    within a week of the procedure and were infected with a dangerous bacterium. The women
    first took oral doses of RU-486, also known as Mifeprex, followed two days later by a
    second drug, misoprostol, to help expel the fetus. But, in a departure from the regimen
    approved by the Food and Drug Administration, they were allowed to insert the second drug
    into their vaginas at home - at a higher dose than first recommended - instead of taking
    it orally in a doctor's office. Those changes and others were justified by scientific
    analyses that the new regimen would be safe and effective and could be used later in a
    pregnancy. But the deaths suggest that the changes may have been imprudent. Health
    authorities will need to sort out which drug, if either, might be at fault, whether
    vaginal insertion is to blame and whether changes in a family of bacteria have made them
    more lethal. Meanwhile, women who live in areas where surgical abortions are hard to
    obtain or who simply prefer pills to surgery should be alert to any symptoms of illness
    after a medical abortion. The danger is slight but for a few women could be catastrophic.
       | 
  
    | Pregnant
    Robot Tests Medical Talents. [United 
States] Noelle's given birth in Afghanistan, California
    and dozens of points in between. She's a lifelike, pregnant robot used in increasing
    numbers of medical schools and hospital maternity wards. The full-sized, blond, pale
    mannequin is in demand because medicine is rapidly abandoning centuries-old training
    methods that use patients as guinea pigs, turning instead to high-tech simulations. It's
    better to make a mistake on a $20,000 robot than a live patient. The Institute of Medicine,
    an arm of the National Academy of Sciences, estimates that 
as many as 98,000 
U.S. patients
    die annually from preventable medical errors. "We're trying to engineer out some of
    the errors," said Dr. Paul Preston, an anesthesiologist at Kaiser Permanente and
    architect of the hospital chain's 4-year-old pregnancy-care training program, in which
    Noelle plays a starring role. "We steal shamelessly from everybody and everywhere
    that has good training programs." | 
  
    | Heart Research
    Turns to Women. [United 
States] Coronary artery disease is the leading cause of death
    in women over 25, killing more than 250,000 a year in the United States. Before they reach
    their 60s, women are less likely than men to develop heart problems, but once the disease
    does occur, women often fare worse than men. Since 1984, more women than men have died
    each year from heart disease, and though overall coronary death rates have dropped in
    recent decades, most of the improvements have been in men. Puzzling differences have
    emerged between men and women with heart disease, making it plain that past studies,
    mostly on men, do not always apply to women. Researchers have come to realize that to
    improve diagnosis and treatment for women, they must sort out the differences. Among the
    differences are these: 1) Women with chest pain and other heart symptoms are more likely
    than men to have clear coronary arteries when tests are performed, a surprising result
    that suggests there may be another cause for their problems. 2) When women do have blocked
    coronary arteries, they tend to be older than men with similar blockages and to have worse
    symptoms, including more chest pain and disability. These women are also more likely to
    have other problems like high blood pressure, high cholesterol and diabetes, which may
    make surgery riskier. And they are more likely than men to develop heart failure, a
    weakening of the heart muscle that can be debilitating and ultimately fatal. 3) When women
    have bypass surgery or balloon procedures for coronary blockages, they are less likely
    than men to have successful outcomes, and they are more likely to suffer from bad side
    effects. 4) Blood tests that reliably pick up signs of heart damage in men do not always
    work in women. 5) Women seem much more likely than men to develop a rare, temporary type
    of heart failure in response to severe emotional stress. | 
  
    | Younger Women at Increased
    Risk for Depression After Heart Attack. [India] Women age 60 years or younger are more
    likely than other patients to be depressed during hospitalization for heart attack,
    according to a study in the April 24 issue of Archives of Internal Medicine, one of the
    JAMA/Archives journals. Depressed heart attack patients are more likely to be hospitalized
    and die of heart problems and tend to have worse health and higher health care costs than
    heart attack patients who are not depressed. Identifying patients who are likely to be
    depressed after heart attack could help physicians screen and treat those at highest risk. |